FDA sets deadline for morning-after pill

Share this article:
The FDA will make a decision on switching Barr Laboratories' emergency contraceptive to OTC status by Sept. 1st.
So stated Secretary of Health and Human Services Michael Leavitt in a letter to Sen. Michael Enzi (R-Wyoming), chairman, Committee on Health, Education, Labor and Pensions.
Subsequently, democratic Sens. Patty Murray of Washington and Hillary Rodham Clinton of New York said in a statement that they would allow a vote on the nomination of Dr. Lester Crawford as FDA commissioner.
Although the joint statement notes continuing "concerns about the lack of leadership and independent decision-making that Dr. Crawford and the FDA have shown in this case," the senators said, "As we have now received a date for decision on Plan B, we have agreed to release our hold on Dr. Crawford's nomination."
Pace, a unit of Lowe Healthcare Worldwide that already handles the professional advertising for Plan B, is set to handle consumer advertising. Barr's proprietary division, Duramed Pharmaceuticals, markets the drug.
If Barr's application is approved, the Rx-to-OTC shift for plan B (levonorgestrel) would apply only to women 16 years of age and up. Women age 15 years of age and younger would still need a prescription.
"Were looking forward to getting a decision in September," Barr spokeswoman Carol A. Cox said.
Leavitt said he wrote the status report on the proposed Plan B switch at Enzi's request. "I am not part of this decision-making process," the secretary wrote, saying that it must be made based on scientific evidence. "However, I have spoken to the FDA, and, based on the feedback I have received, the FDA will act on this application by Sept. 1, 2005."
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...